Patents by Inventor James J. Blake

James J. Blake has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200317665
    Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: March 31, 2020
    Publication date: October 8, 2020
    Applicant: Array BioPharma Inc.
    Inventors: James F. BLAKE, Mark Laurence BOYS, Mark Joseph CHICARELLI, Adam W. COOK, Mohamed S. A. ELSAYED, Jay Bradford FELL, John P. FISCHER, Ronald Jay HINKLIN, Yutong JIANG, Oren T. MCNULTY, Macedonio J. MEJIA, Martha E. RODRIGUEZ, Christina E. WONG
  • Patent number: 10752769
    Abstract: The present invention provides an elastomeric composition comprising: at least one first elastomer; at least one first hydrocarbon polymer additive; and at least one second hydrocarbon polymer additive; wherein each of the first hydrocarbon polymer additive and the second hydrocarbon polymer additive is selected from the group consisting of: C5 aliphatic resins, C9 aromatic resins, mixed C5/C9 resins, pure aromatic monomer resins, dicyclopentadiene (DCPD) resins, aromatic modified cycloaliphatic resins, coumarone indene resins, rosin resins, rosin esters, terpene resins, modified terpene resins, terpene phenolic resins, and hydrogenated resins thereof. The composition may further comprise a second elastomer which is immiscible with the first elastomer.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: August 25, 2020
    Assignee: ExxonMobil Chemical Patents Inc.
    Inventors: Xiao-Dong Pan, Bobby J. Harper, Jr., James M. Blake
  • Patent number: 10731620
    Abstract: A system for starting an engine of a vehicle has a fuel injector injecting fuel into a closed intake port to form an air fuel mixture. The system also includes an actuator rotating a crankshaft in a first direction to open the intake port by moving a piston within a cylinder coupled to the crankshaft. A combustion chamber defines between the cylinder and the port receiving the air fuel mixture through the intake port. The actuator rotates the crankshaft in a second direction to close the intake port. A spark plug ignites the air fuel mixture to start the engine. The engine also includes many other disclosed features.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: August 4, 2020
    Assignee: Polaris Industries Inc.
    Inventors: Dallas J. Blake, James A. Barczak, Lawrence J. Hosaluk, Darren J. Hedlund, Oliver J. Young, Matthew D. Reeves, Joseph D. Tharaldson, Chad A. Dale, Stephen G. Crain, Trevor F. Rhodes
  • Patent number: 10724102
    Abstract: Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a Trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a Trk inhibitor, methods of predicting the efficacy of a Trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a Trk inhibitor-resistant cancer, and methods of determining the presence of a Trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the point mutations in NTRK1 and/or NTRK2 and/or NTRK3.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: July 28, 2020
    Assignees: Loxo Oncology, Inc., Array BioPharma, Inc.
    Inventors: Nisha Nanda, Joshua H. Bilenker, James F. Blake, Gabrielle R. Kolakowski, Barbara J. Brandhuber, Steven W. Andrews
  • Patent number: 10689377
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: June 23, 2020
    Assignees: Mirati Therapeutics, Inc., Array Biopharma Inc.
    Inventors: James F. Blake, Laurence E. Burgess, Mark Joseph Chicarelli, James Gail Christensen, Adam Cook, Jay Bradford Fell, John P. Fischer, Matthew Arnold Marx, Macedonio J. Mejia, Pavel Savechenkov, Guy P. A. Vigers, Christopher Ronald Smith, Martha E. Rodriguez
  • Publication number: 20200182164
    Abstract: A method and system for operating a two-stroke engine includes a fuel system comprising a fuel pressure sensor, fuel temperature sensor and a fuel injector and a controller in communication with the fuel pressure sensor and fuel temperature sensor. The controller controls the fuel injector with a fuel pulsewidth determined by determining a beginning time of a window for measuring fuel pressure, determining an ending time of the window, measuring fuel pressure between the beginning time and the ending time, determining a fuel pulsewidth based on the fuel pressure and fuel temperature and injecting fuel into the two-stroke engine in response to a desired fuel mass.
    Type: Application
    Filed: November 26, 2019
    Publication date: June 11, 2020
    Applicant: Polaris Industries Inc.
    Inventors: James H. BUCHWITZ, Ralph W. LAUZZE, III, Eric L. GAUSEN, Andreas H. BILEK, Dallas J. BLAKE, Derek D. ZIMNEY, Lucas R. SALFER, Ron DANIELSON
  • Patent number: 10655186
    Abstract: Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a Trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a Trk inhibitor, methods of predicting the efficacy of a Trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a Trk inhibitor-resistant cancer, and methods of determining the presence of a Trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the point mutations in NTRK1 and/or NTRK2 and/or NTRK3.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: May 19, 2020
    Assignees: Loxo Oncology, Inc., Array Biopharma, Inc.
    Inventors: Nisha Nanda, Joshua H. Bilenker, James F. Blake, Gabrielle R. Kolakowski, Barbara J. Brandhuber, Steven W. Andrews
  • Patent number: 10648399
    Abstract: A two cycle engine having a block defining an exhaust port and a cylinder, a head, and a piston defining a combustion chamber is disclosed. The exhaust port has a resonant frequency that causes a portion of the combusted and uncombusted exhaust gasses to flow from the exhaust system and back into the combustion chamber. At a speed above the predetermined speed, a majority of the portion of the combusted and uncombusted exhaust gasses flows from the exhaust system and back into the combustion chamber without engaging the skirt of the piston.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: May 12, 2020
    Assignee: Polaris Industries Inc.
    Inventors: James A Barczak, Lawrence J. Hosaluk, Dallas J. Blake, Darren J. Hedlund
  • Patent number: 10633381
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: April 28, 2020
    Assignees: Mirati Therapeutics, Inc., Array BioPharma Inc.
    Inventors: James F. Blake, Laurence E. Burgess, Mark Joseph Chicarelli, James Gail Christensen, Jay Bradford Fell, John P. Fischer, John J. Gaudino, Erik James Hicken, Ronald Jay Hinklin, Matthew Randolf Lee, Matthew Arnold Marx, Macedonio J. Mejia, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P. A. Vigers, Henry J. Zecca
  • Patent number: 10555944
    Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: February 11, 2020
    Assignee: Eli Lilly and Company
    Inventors: Steven W. Andrews, Sean Aronow, James F. Blake, Barbara J. Brandhuber, Adam Cook, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L. McKenney, Oren T. McNulty, Andrew T. Metcalf, David A. Moreno, Tony P. Tang, Li Ren
  • Publication number: 20200030311
    Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Application
    Filed: September 23, 2019
    Publication date: January 30, 2020
    Inventors: Steven W. ANDREWS, Sean ARONOW, James F. BLAKE, Barbara J. BRANDHUBER, James COLLIER, Adam COOK, Julia HAAS, Yutong JIANG, Gabrielle R. KOLAKOWSKI, Elizabeth A. McFADDIN, Megan L. McKENNEY, Oren T. McNULTY, Andrew T. METCALF, David A. MORENO, Ginelle A. RAMANN, Tony P. TANG, Li REN, Shane M. WALLS
  • Patent number: 10519126
    Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: December 31, 2019
    Assignees: Array BioPharma Inc., Genentech, Inc.
    Inventors: James F. Blake, Mark Joseph Chicarelli, Rustam Ferdinand Garrey, John Gaudino, Jonas Grina, David A. Moreno, Peter J. Mohr, Li Ren, Jacob Schwarz, Huifen Chen, Kirk Robarge, Aihe Zhou
  • Patent number: 10520744
    Abstract: Inhibiting formation of optical artifacts in a multi-layer film polarizer of an optical imaging assembly that includes a polarizing beam splitter. The beam splitter may include a multilayer reflective polarizing film having at least two materials, one of which may exhibit birefringence after uniaxial orientation; an adhesive disposed on the multilayer reflective polarizing film; and at least a first prism disposed on the adhesive. The adhesive may include a plasticizer for inhibiting formation of optical artifacts in the polarizing film.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: December 31, 2019
    Assignee: 3M INNOVATIVE PROPERTIES COMPANY
    Inventors: James P. DiZio, Maureen C. Nelson, Kathleen E. Hoelscher, Beverly J. Blake, Erin L. Coleman, Charles L. Bruzzone
  • Patent number: 10441581
    Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: October 15, 2019
    Assignee: Array Biopharma Inc.
    Inventors: Steven W. Andrews, Sean Aronow, James F. Blake, Barbara J. Brandhuber, James Collier, Adam Cook, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L. McKenney, Oren T. McNulty, Andrew T. Metcalf, David A. Moreno, Ginelle A. Ramann, Tony P. Tang, Li Ren, Shane M. Walls
  • Publication number: 20190270749
    Abstract: Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.
    Type: Application
    Filed: May 17, 2019
    Publication date: September 5, 2019
    Applicant: Array BioPharma Inc.
    Inventors: Shelley Allen, Steven Wade Andrews, James F. Blake, Barbara J. Brandhuber, Julia Haas, Yutong Jiang, Timothy Kercher, Gabrielle R. Kolakowski, Allen A. Thomas, Shannon L. Winski
  • Patent number: 10378068
    Abstract: Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a Trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a Trk inhibitor, methods of predicting the efficacy of a Trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a Trk inhibitor-resistant cancer, and methods of determining the presence of a Trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the point mutations in NTRK1 and/or NTRK2 and/or NTRK3.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: August 13, 2019
    Assignees: Loxo Oncology, Inc., Array BioPharma, Inc.
    Inventors: Nisha Nanda, Joshua H. Bilenker, James F. Blake, Gabrielle R. Kolakowski, Barbara J. Brandhuber, Steven W. Andrews
  • Patent number: 10370727
    Abstract: Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a Trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a Trk inhibitor, methods of predicting the efficacy of a Trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a Trk inhibitor-resistant cancer, and methods of determining the presence of a Trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the the point mutations in NTRK1 and/or NTRK2 and/or NTRK3.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: August 6, 2019
    Assignees: Loxo Oncology, Inc., Array BioPharma, Inc.
    Inventors: Nisha Nanda, Joshua H. Bilenker, James F. Blake, Gabrielle R. Kolakowski, Barbara J. Brandhuber, Steven W. Andrews
  • Patent number: 10351575
    Abstract: Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: July 16, 2019
    Assignee: Array BioPharma Inc.
    Inventors: Shelley Allen, Steven Wade Andrews, James F. Blake, Barbara J. Brandhuber, Julia Haas, Yutong Jiang, Timothy Kercher, Gabrielle R. Kolakowski, Allen A. Thomas, Shannon L. Winski
  • Patent number: 10330096
    Abstract: An apparatus and method for controlling an electric oil pump with a pump control signal generated by an electronic control unit (ECU) of a vehicle. The pump control signal has a variable drive time portion during which the electric oil pump is actuated to supply oil to an engine of the vehicle and a variable cycle time defining a frequency of the pump control signal.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: June 25, 2019
    Assignee: Polaris Industries Inc.
    Inventors: Dallas J. Blake, James H. Buchwitz
  • Publication number: 20190183886
    Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Application
    Filed: October 29, 2018
    Publication date: June 20, 2019
    Inventors: Steven W. Andrews, Sean Aronow, James F. Blake, Barbara J. Brandhuber, Adam Cook, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L. McKenney, Oren T. McNulty, Andrew T. Metcalf, David A. Moreno, Tony P. Tang, Li Ren